Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 1.95B |
| Revenue (ttm) | 411.35M |
| Net Income (ttm) | 65.12M |
| Shares Out | 118.12M |
| EPS (ttm) | 0.54 |
| PE Ratio | 30.54 |
| Forward PE | 15.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 658,526 |
| Open | 16.55 |
| Previous Close | 16.40 |
| Day's Range | 16.31 - 16.85 |
| 52-Week Range | 11.09 - 17.50 |
| Beta | 0.89 |
| Analysts | Strong Buy |
| Price Target | 27.17 (+64.77%) |
| Earnings Date | May 8, 2024 |
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type... [Read more]
Financial Performance
In 2023, CPRX's revenue was $398.20 million, an increase of 85.90% compared to the previous year's $214.20 million. Earnings were $71.41 million, a decrease of -14.05%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CPRX stock is "Strong Buy." The 12-month stock price forecast is $27.17, which is an increase of 64.77% from the latest price.
News
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET
Jim Cramer lays out his top small-cap healthcare picks
'Mad Money' host Jim Cramer shares his small-cap healthcare stock picks.
Jim Cramer recommends five small-cap health-care stocks
CNBC's Jim Cramer said he thinks it could be a good year for small cap stocks and shared his top picks.
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing...
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and...
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in the United...
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de...
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Qua...
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety P...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
CORAL GABLES, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today reported that it has closed its underwritten public offering of ...
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,0...
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public offering ...
20 favorite small-cap stocks for 2024 among Wall Street analysts
The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and ...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most S...
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted t...
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and ...
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $(0.29) Diluted, Impacted by an $81.5 Million One Time Non-Recurring IPR&D E...
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...